Sun Pharma gets FDA nod for generic Atelvia

Sun Pharma has received the Food and Drug Administration’s approval for risedronate delayed-release tablets in a dosage strength of 35 mg.

The product is the generic of Actavis’ Atelvia.

Risedronate delayed-release 35mg tablets have a market value of $17 million, according to IQVIA.

The product is expected to be launched in the third quarter.